Agents enhancing HuR/ELAV protein levels for use in the treatment of BRAF-mutated cancers
US10772875B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 14, 2018 |
| Grant date | Sep 15, 2020 |
| Priority date | — |
| Expiry date | Mar 14, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/91215
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to agents enhancing HuR/ELAV levels for use in the treatment of BRAF-mutated cancers and uses thereof. In particular, the invention relates to the use of agents enhancing HuR/ELAV levels in combination with BRAF inhibitors for the treatment of BRAF-mutated cancers, in particular melanoma and to methods for identifying agents useful for potentiating the effects of BRAF inhibitors, when used in combination.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.